RAPT Therapeutics Announces Late-Breaking Oral Presentation of Positive Results from Phase 1b Trial of RPT193 at the 30th European Academy of Dermatology and Venereology Congress

NEXT STORY
Adial Pharmaceuticals Announces Greater Than 50% of Patients Expected to Complete ONWARD™ Phase 3 Trial of AD04 for the Treatment of Alcohol Use Disorder Have Completed the Full 24-Week Treatment Period – Trial Completion Anticipated Q1 2022
PREV STORY
Todos Medical Announces Positive Observational Trial Results for Oral Antiviral 3CL Protease (MPro) Inhibitor Tollovir®
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Positive phase III results show Xofluza reduces risk of developing flu after contact with an infected person by 86%

author_avatar
NASDAQ Market News

Trillium Announces Voting Results From the Annual and Special Meeting of Shareholders

author_avatar
NASDAQ Market News

Chembio Diagnostics to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020

author_avatar
NASDAQ Market News